Clinical Trial Update: Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating safety and immunogenicity of two different serotype 2 potencies of Takeda's tetravalent dengue vaccine in adults in Singapore.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• TDV (Takeda dengue vaccine)

Snippet

Sponsor: Takeda | Conditions: Dengue Fever | Phase 2 | Status: COMPLETED | Results posted: 2019-08-28